诺和灵N联合瑞格列奈、拜唐苹治疗继发磺酰脲类药物失效的2型糖尿病疗效观察  

作　　者：梁伟华[1] 

机构地区：[1]广东江门市新会区会城医院内科,529100

出　　处：《中国社区医师（医学专业）》2011年第35期74-75,共2页

摘　　要：目的:观察诺和灵N联合瑞格列奈、拜唐苹对继发性磺酰脲类药物失效的2型糖尿病的临床疗效。方法:对41例继发性磺酰脲类失效的2型糖尿病(T2DM)患者停服包括磺酰脲类在内的降糖药物,改服瑞格列奈和拜唐苹,睡前注射诺和灵N。观察治疗前后空腹血糖、餐后血糖、HbA1c、体重指数(BMI)、低血糖发生等情况。结果:诺和灵N联合瑞格列奈、拜唐苹治疗前后,可见空腹血糖、餐后2小时血糖、HbA1c较前显著下降,BMI无明显变化,低血糖发生率低。结论:诺和灵N联合瑞格列奈、拜唐苹治疗继发磺酰脲类药物失效的2型糖尿病患者,是一种安全有效的治疗方法。Objective：To observe curative effect of Novolin N,repaglinide tablets and Acarbose therapy in patients with secondary sulfonylurea drug failure type 2 diabetes.Method：41 cases secondary failure sulfonylurea class hypoglycemic T2DM patients stop taking,use repaglinide and Baitang Ping,bedtime injection of Novolin N.Observed before after treatment fasting blood glucose,postprandial blood glucose,HbA1c,BMI,low blood sugar.Result：Before and after treatment,showing fasting blood glucose,postprandial 2h plasma glucose,HbA1c decreased significantly than before,BMI was no change,low incidence of low blood sugar.Conclusion：Novolin N joint repaglinide,Baitang Ping treatment of secondary failure of sulfonylurea drugs in patients with type 2 diabetes,is a safe effective treatment.

关 键 词：2型糖尿病 磺酰脲类降糖药 诺和灵N 瑞格列奈 拜唐苹 

分 类 号：R587.1[医药卫生—内分泌]